GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing.
生物技術公司GeneDx Holdings Corp. (NASDAQ:WGS) 在2024年Russell 2000指數中取得了最大的收益，因爲公司正在向更全面的基因檢測發展。
The Maryland-based company's shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview.
據Tradingview稱，這家總部位於馬里蘭州的公司股價已在本年度中午之前上漲了1,101%。
Goldman Sachs analyst Matthew Sykes attributes much of GeneDX's positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person's DNA to find genetic variations.
高盛（Goldman Sachs）分析師Matthew Sykes認爲，GeneDX的積極勢頭很大程度上要歸功於轉變其測試方法。該公司從基於面板的測試轉向基因組測試，後者分析一個人大部分的DNA來發現基因變異。
Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance
閱讀更多：GeneDx在Q1業績中發佈超預期業績後，股價上漲，提高FY24指引。
"We remain optimistic about WGS's continued focus on converting its mix shift of panel-based tests to whole exome/genome-based tests," Sykes wrote in a note on Wednesday.
Sykes在週三的一份報告中寫道：“我們仍然看好WGS繼續專注於將面板測試轉換爲全外顯子/基因組測試，”
"As of 1Q24, 30% of their tests were exome/genome-based, whereas this metric was 16% in 1Q23."
“截至2024年第一季度，他們的30%測試是基於全外顯子/基因組，而在2023年第一季度，這個指標爲16%。”
He said the transition has expanded the company's margins from 33% in the first quarter of 2023 to 61% in this year's first quarter.
他說，這一轉變使得該公司的利潤率從2023年第一季度的33%提高到今年第一季度的61%。
"We see gross margins continuing to improve going forward, yet see more moderated growth in out years, reaching the mid-high 60% range exiting 2026," he wrote.
他寫道：“我們預計毛利率將繼續改善，但未來增長將持續緩慢，到2026年，毛利率尚可達到中高60%的水平。”
"We see this mix shift evolution as the key driver of WGS's growth in the near term given their initial focus on rare disease/pediatrics."
他寫道：“鑑於他們最初專注於罕見疾病/小兒科，我們認爲這種混合轉變的進化是WGS短期增長的關鍵驅動因素。”
Goldman Sachs maintains revenue estimates for GeneDx at $243 million for 2024, $269 million for 2025 and $306 million for 2026. It expects the company to post losses per share of $1.07 for this year and $0.21 for next year and earnings per share of $0.35 for 2026.
高盛維持對GeneDx 2024年的營業收入預期爲$24300萬，2025年爲$26900萬，2026年爲$30600萬。它預計公司今年每股虧損$1.07，明年爲$0.21，2026年每股收益爲$0.35。
It has given GeneDx a Neutral rating and has increased its price target on the stock from $12.50 to $28.
它給GeneDx股票一箇中立評級，並將其股票價格目標從$12.50上調至$28。
Analysts expect GeneDx to post a $0.30 loss per share when it reports second-quarter earnings on July 30, up from a $0.33 loss per share registered for the first quarter, according to Benzinga Pro.
據Benzinga Pro報道，分析師預計GeneDx在7月30日公佈第二季度業績時每股虧損$0.30，而第一季度的每股虧損爲$0.33。
GeneDx has distanced itself from stocks held by runner-up small-cap companies Massachusetts-based Corbus Holdings Inc. (NASDAQ:CRBP) and Root, Inc. (NASDAQ:ROOT).
GeneDx已與小型公司馬薩諸塞州的Corbus Holdings Inc. (NASDAQ:CRBP)和在線汽車保險公司Root, Inc. (NASDAQ:ROOT)保持距離。
Corbus has risen 834% since the beginning of 2024, while Root, an Ohio-based online car insurance company, has gained 670%.
自2024年初以來，Corbus上漲了834%，而總部位於俄亥俄州的在線汽車保險公司Root上漲了670%。
Price Action: GeneDx has slipped 3.36% to $32.18 by Thursday's midday trading, while Corbus has fallen 5.26% to $55.86 and Root has risen 1.49% to $80.59.
GeneDx的股價在週四中午交易時下跌3.36%至$32.18，而Corbus的股價下跌了5.26%至$55.86，Root的股價上漲了1.49%至$80.59。
Other leading small-cap stocks on Russell 2000
Russell 2000指數中的其他領先小市值股票
Below are the remaining companies that round out the top-10 list of top performers in the Russell 2000.
下面是Russell 2000指數中表現最好的前10家公司的列表：
- Elevation Oncology Inc. (NASDAQ:ELEV), up %411%.
- Dave Inc. (NASDAQ:DAVE), up 403%.
- Avidity Biosciences, Inc. (NASDAQ:RNA), up 387%.
- Sezzle Inc. (NASDAQ:SEZL), up 322%.
- Candel Therapeutics, Inc. (NASDAQ:CADL), up 321%.
- NuScale Power Corporation (NYSE:SMR), up 303%.
- Janux Therapeutices, Inc. (NASDAQ:JANX), up 302%.
- Elevation Oncology Inc. (NASDAQ:ELEV)，漲%411。
- Dave Inc.(NASDAQ：DAVE)，漲403%。
- Avidity Biosciences Inc.(NASDAQ: RNA)，漲387%。
- Sezzle公司（納斯達克：SEZL）漲了322%。
- Candel Therapeutics公司，Inc.（納斯達克：CADL）漲了321%。
- NuScale Power Corporation公司（紐交所：SMR）漲了303%。
- Janux Therapeutices公司，Inc.（納斯達克：JANX）漲了302%。
Read Now:
立即閱讀：
- Small Cap Stocks Are Having A Moment: Russell 2000 Notches Best 5-Day Rally In Over 4 Years
- 小盤股正迎來大好時機：羅素2000指數創下4年來5天的最佳漲勢。
Image: Shutterstock
圖片：shutterstock